posted on 2023-02-22, 14:46authored byAilise Carleton, Brian Casserly, Lorraine Power, Barry Linnane, Grainne O'Flaherty, James Powell, Peig Hartnett, Jonathan Collins, Philip Murphy, Dervla Kenna, Nuala H. O'Connell, Colum P. DunneColum P. Dunne
Introduction: Bordetella petrii is an emerging pathogen. Whilst association with cystic fibrosis
(CF) has been described previously, this is the first report to our knowledge of multidrug-resistant
B. petrii incidence in an Irish CF patient population.
Case presentation: Using a case series of four adult CF patients with varying baselines of
health, one of whom was asymptomatic, this report attempts correlation of B. petrii colonization,
by one common strain, with incidence of acute exacerbation of symptoms. As definitive
guidelines for antimicrobial sensitivity/resistance do not exist for B. petrii, we completed a
systematic review of available literature to collate evidence of antimicrobial efficacy against
B. petrii. Comparison with the isolates in this study indicated B. petrii sensitivity to piperacillin/
tazobactam and minocycline but resistance to antimicrobials in the macrolide, other b-lactam and
fluoroquinolone groups.
Conclusion: To our knowledge, this is the first report of multiple CF patients sharing a strain of
B. petrii. Furthermore, B. petrii may be under-identified in CF patients and should be considered
when evaluating exacerbation of CF symptoms.
History
Publication
JMM Case Reports;1
Publisher
Society for General Microbiology
Note
peer-reviewed
Language
English
Also affiliated with
4i - Centre for Interventions in Infection, Inflammation & Immunity